2Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine triad expession in colorectal carcinomas and premalignant lesions. Cancer Res, 2000,60 : 18-21.
3Li J, Yen C, Liaw D,et al. PTEN, a putive protein tyrosine phosphatase gene mutated in humun brain breast and prostate cencen. Science, 1997, 275 : 1943-1947.
4Steck PA, Pershouse MA. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23, 3 that is mutated in mutiple advanced cancer. Nature Genetics, 1997, 15:386-359.
5Li DM, Sun H. Tepl encoded by a candidate tumor supressor locus, is a novel protein thyrosine phosphatase regulated by transforming growth factor β1. Cancer Res, 1997, 57: 2130-2136.
6De Graffenried LA, Fulcher L, Friedriehs WE, et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol ,2004,15 : 1510-1516.
7Tunca B, Bekar A, Cecener G, et al. Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme. J Neuro Oncology, 2006,3:263-269.
9Tokunaga E, Oki E, Kimura Y,et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpres- sion enhances the Akt activity thus leading to a negative pro- gesterone receptor expression in breast carcinoma. Breast Cancer Res Treatt, 2006, 3: 249-257.
10Harima Y, Sawada S, Nagata K,et al. Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy[J]. Int J Oncol,2001,18(2) :493 -498.
3Li J, Yen C, Liaw D, Podsypanina K, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997, 275(5308): 1943-1947.
4Tamura M, Gu J, Tran H, et al. PTEN gene and integrin signaling in cancer. J Natl Cancer Inst, 1999, 91(21 ):1820-1828.
5Alexiou GA, Voulgaris S. The role of the PTEN gene in malignant gliomas.Neurol Neurochir Pol, 2010, 44( 1 ):80-86.
6Tokunaga E, Oki E, Kimura Y, Yamanaka T, et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression en- hances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat, 2007, 101 (3): 249-257.
7Aveyard JS, Skilleter A, Habuchi T, et al. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer, 1999, 80(5-6): 904-908.
8Tanaka M, Koul D, Davies MA, et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene, 2000, 19(47): 5406-5412.
